BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03083691
• Other study ID #: Uni-Koeln-2785
• Secondary ID: 2016-003334-25
• Status: Completed
• Phase: Phase 2
• Start date: April 13, 2017
• Est. completion date: November 20, 2023

Study information

• Verified date: January 2024
• Source: Lung Cancer Group Cologne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BIOLUMA is a multicentric non-randomised phase II trial in patients with non-squamous non-small cell lung cancer (NSCLC) (Cohort 1) and patients with small-cell lung cancer (SCLC) (Cohort 2) after failure of platinum-based first-line therapy. NSCLC patients are treated with nivolumab until disease progression and subsequently receive a combination therapy of nivolumab and ipilimumab. SCLC patients receive four cycles of nivolumab in combination with ipilimumab and subsequent nivolumab monotherapy. Primary endpoint for both cohorts is overall response rate of combination therapy.

Within the diagnostic part tumor biopsies will be analysed. Tumor tissue will be obtained before initiation of therapy and after progression on nivolumab monotherapy before addition of ipilimumab in Cohort 1 and after completion of the four nivolumab/ipilimumab combination cycles before continuation of nivolumab monotherapy in Cohort 2, respectively. Flow cytometry of blood samples and microbiome analysis of deep rectal swaps are performed prior to therapy as well as during course of treatment.

Cohort 1 (NSCLC) is closed for enrollment due to Sponsor decision.

In Cohort 2 (SCLC) a prescreening for high Tumor Mutation Burden is necessary before enrollment.

Description:

Cohort 2 (SCLC) has been subdivided by amendment in Cohort 2a without prescreening and Cohort 2b with TMB-prescreening. For Cohort 2a enrollment has been stopped in December 2017. Cohort 2b is closed for enrollment as the cohort is fully recruited.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: November 20, 2023
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Note: Both cohorts are closed for enrollment

Inclusion Criteria:

• Cohort 1: Subjects with histologically or cytologically confirmed advanced non-squamous non-small cell lung cancer who present with stage IIIB or stage IV disease after failure of platinum-based first-line therapy. Subjects who received adjuvant/neoadjuvant therapy or definitive chemoradiation and develop recurrence or progression, with evidence of stage IIIB-IV disease within 6 months after completion of therapy, are eligible.

• Cohort 2: Subjects in Cohort 2 have to undergo Prescreening to determine Tumor Mutation Burden. Only patients with high Tumor Mutation Burden are eligible.

Subjects with histologically or cytologically confirmed limited-stage or extensive-stage small cell lung cancer after failure of platinum-based first-line therapy.

Cohort 1 and Cohort 2:

• Signed and dated written informed consent form must be obtained before the performance of any study-specific procedure

• Male or female patients = 18 years of age

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

• Subjects must be willing to undergo the baseline biopsie during screening, if medically feasible

• Measurable disease by CT or MRI per RECIST 1.1 criteria.

• Screening laboratory values must meet the following criteria and should be obtained within 28 days prior to registration: white blood cell count = 2000/µL, Neutrophils = 1500/µL, Platelets = 100 x103/µL, Hemoglobin > 9.0 g/dL, Serum creatinine = 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) = 40 mL/min, AST/ALT = 3 x ULN for patients without liver metastasis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 5 x ULN for patients with liver metastasis, Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)

• Prior chemotherapy must have been completed at least 4 weeks before study drug administration, and all AEs have either returned to baseline or stabilized.

• Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration

• Prior targeted therapy must have been completed at least 4 weeks prior to study drug administration

• Cohort 1 and 2a: Subjects with central nervous system (CNS) metastasis are eligible if CNS metastases are treated and subjects have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 28 days prior to first dose of study drug administration. In addition, subjects must either be off corticosteroids or on a stable dose or decreasing dose of = 10 mg daily prednisone (or equivalent).

Cohort 2b: Subjects with CNS metastases are eligible. Radiation of CNS metastases at initiation of study drug treatment is allowed if the trial subject has target lesions outside of the brain.

• Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for 5 month after the last dose of study drug.

• Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of b-HCG) within 24 hours prior to the start of nivolumab.

• Women must not be breastfeeding.

• Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 7 month post treatment completion.

Exclusion Criteria:

• Subjects with squamous cell NSCLC

• Cohort 1: activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation

• Cohort 1 and 2a only: More than one prior line of chemotherapy for treatment of advanced disease Note for Cohort 2b: inclusion of patients who received 2nd line treatment is allowed if 2nd line did not include an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody as monotherapy or in combination with other than platinum-based chemotherapy.

• Medical conditions associated with significantly increased risk for bleeding complications caused by biopsy procedures (e.g. known coagulopathies, therapeutic anticoagulation)

• Cohort 1 and 2a only: Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 4 weeks after treatment is complete and within 28 days prior to the first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.

• Presence or history of any other primary malignancy other than NSCLC for Cohort 1 and SCLC for Cohort 2 within 5 years prior to enrolment into the trial, except for adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma.

• Active, known or suspected autoimmune disease. Subjects are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

• Positive test for hepatitis B or hepatitis C indicating acute or chronic infection

• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.

Note for Cohort 2b: higher doses of corticosteroids for patients receiving radiation therapy of brain metastases are allowed.

• Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

• Prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.

Note: SCLC-Patients who where treated with a combination therapy of platinum-based chemotherapy together with anti-PD-1/PD-L1 treatment are eligible.

• Prisoners or subjects who are involuntarily incarcerated.

• Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a subject's ability to comply with the study requirements, substantially increase risk to the subject, or impact the interpretability or study results.

• Allergies and Adverse Drug Reaction: History of allergy to study drug components and history of severe hypersensitivity reaction to any monoclonal antibody

• Current treatment within another therapeutic clinical trial

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Small Cell
• Carcinoma, Small Cell Lung
• Small Cell Lung Carcinoma

Intervention

Drug:
• Nivolumab, Ipilimumab
Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
• Nivolumab, Ipilimumab
Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.

Locations

Country	Name	City	State
Germany	Uniklinik RWTH - Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzellentransplantation	Aachen	North Rhine-Westphalia
Germany	Evangelische Lungenklinik Berlin	Berlin
Germany	Universitätsklinikum Bonn - Medizinische Klinik und Poliklinik III	Bonn	North Rhine-Westphalia
Germany	Kliniken der Stadt Köln - Lungenkrebszentrum Köln-Merheim	Cologne	North Rhine-Westphalia
Germany	University Hospital Cologne	Cologne	North Rhine-Westphalia
Germany	St.-Johannes-Hospital Dortmund	Dortmund	North Rhine-Westphalia
Germany	Uniklinik Düsseldorf - Klinik für Hämatologie und Onkologie	Düsseldorf	North Rhine-Westphalia
Germany	Malteser Krankenhaus St. Franziskus-Hospital	Flensburg	Schleswig-Holstein
Germany	Universitätsklinikum Frankfurt - Medizinische Klinik II	Frankfurt am Main	Hessen
Germany	Lungenklinik Hemer	Hemer	North Rhine-Westphalia
Germany	Klinikum Kassel - Klinik für Hämatologie und Onkologie	Kassel	Hessen
Germany	SLK-Fachklinik Löwenstein	Löwenstein	Baden-Wuerttemberg
Germany	Universitätsklinikum Münster - Medizinische Klinik A, Pneumologie	Münster	North Rhine-Westphalia
Germany	Pius Hospital Oldenburg	Oldenburg	Lower Saxony
Germany	Universitätsklinikum Tübingen, Innere Medizin VIII - Medizinische Onkologie und Pneumologie	Tübingen	Baden-Wuerttemberg
Germany	Universitätsklinikum Würzburg - Comprehensive Cancer Center Mainfranken	Würzburg	Bavaria

Sponsors (2)

Lead Sponsor	Collaborator
Lung Cancer Group Cologne	Bristol-Myers Squibb

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.	ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).	From beginning of combination therapy until the date of first documented progression, or date of death of any cause, whichever occurs first, assessed up to 120 months.
Primary	Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.	ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).	From beginning of combination therapy until the date of first documented progression, or date of death of any cause, whichever occurs first, assessed up to 120 months.
Secondary	Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy	Time from date of first dose to the date of death to any cause.	From date of first dose until death, withdrawal of informed consent or lost to follow-up, through study completion, an average of 1 year, up to 120 months.
Secondary	Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy	Time from the date of first dose to first documentation of objective disease progression or to death on study due to any cause, whichever occurs first.	From date of first dose to first documentation of objective disease progression or to death on study due to any cause, an average of 6 months, up to 120 months.
Secondary	Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy	Time from the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of objective disease progression or to death due to any cause, whichever occurs first	First on-study tumor assessment is performed at Week 9 in Cohort 1 and at Week 5 in Cohort 2 and subsequently every 8 weeks through study completion, an average of 1 year.
Secondary	Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy	Adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)	From initiation of study drug, continuously during the treatment period and for a minimum of 100 days following the last dose of study treatment.
Secondary	Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy	Serious adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)	Following the subject's written consent, SAEs are collected that occur within survival follow-up through study completion, an average of 6 months. For subjects who did not receive study medication, SAEs are collected until resolved.